Logo

Jazz' Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Share this
Jazz' Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Jazz' Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Shots:

  • NICE has issued a positive Final Appraisal Document which recommends Sunosi (75/150mg, qd) as an option treatment for adults with EDS caused by narcolepsy with/out cataplexy. The therapy will be available in England and Wales
  • The recommendation is based on the P-III TONES studies to evaluate Sunosi vs PBO in adults patients with EDS. The results demonstrated a clinical effectiveness and safety profile of solriamfetol in patients with narcolepsy & maintain its effect after 6mos. of treatment
  • Solriamfetol is dual-acting dopamine and noradrenaline reuptake inhibitor & is designed to improve wakefulness and reduce EDS in adult patients with narcolepsy

  Ref: Jazz  | Image: Jazz

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions